Clinical trial
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
NCT05619783 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 29, 2022
- Completion date
- October 30, 2024
- Enrollment
- 352 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.